# Juan J. Gómez‐Reino

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/juan-j-gomez-reino/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,340 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 93 |
| i10-index | 306 |
| Last Known Institution | Hospital Clínico Universitario de Valencia |
| OpenAlex ID | https://openalex.org/A5071926023 |
| ORCID iD | https://orcid.org/0000-0001-5229-6294 |
| Works | 510 |

## Researcher papers

- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Treating rheumatoid arthritis to target: recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-recommendations-of-an-international-task/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-2014-update-of-the-recommendations-of-an/)
- [American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials](https://scholariq.org/papers/american-college-of-rheumatology-european-league-against-rheumatism-provisional/)
- [Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study](https://scholariq.org/papers/comparison-of-tocilizumab-monotherapy-versus-methotrexate-monotherapy-in/)
- [The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement](https://scholariq.org/papers/the-risk-of-tuberculosis-related-to-tumour-necrosis-factor-antagonist-therapies/)
- [A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone](https://scholariq.org/papers/a-phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Osteoarthritis Treatment and Mechanisms](https://scholariq.org/topics/osteoarthritis-treatment-and-mechanisms/)

## Researcher university

- [Hospital Clínico Universitario de Valencia](https://scholariq.org/institutions/hospital-clinico-universitario-de-valencia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.